Diffuse large B cell lymphoma

Haouimi, Ammar

doi:10.53347/rid-91348

Cited by 1 publication

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diffuse large b-cell lymphoma (DLBCL) is the most common type of lymphoma. 1 It presents as a rapidly growing mass, either at a nodal or extra nodal site, and represents up to 25% of all non-Hodgkin lymphomas. 1,2 This cancer occurs more frequently in men and whites with a median age at diagnosis of 70 years.…”

Section: Introductionmentioning

confidence: 99%

“…1 It presents as a rapidly growing mass, either at a nodal or extra nodal site, and represents up to 25% of all non-Hodgkin lymphomas. 1,2 This cancer occurs more frequently in men and whites with a median age at diagnosis of 70 years. 1,3 Although it is a potentially curable malignancy, it is aggressive in nature and can be associated with a poor prognosis with a 5-year survival rate of approximately 78% in younger patients and only 54% in older patients >65 years old.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 This cancer occurs more frequently in men and whites with a median age at diagnosis of 70 years. 1,3 Although it is a potentially curable malignancy, it is aggressive in nature and can be associated with a poor prognosis with a 5-year survival rate of approximately 78% in younger patients and only 54% in older patients >65 years old. 4 Furthermore, patients with DLBCL experience a high physical and psychosocial burden and this highlights the need to focus on quality of life while managing their disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and Predictors of Palliative Care Utilization among Hospitalized Patients with Diffuse Large B-Cell Lymphoma

2022

View full text Add to dashboard Cite

Objective: Research has shown that palliative care improves the quality of life of cancer patients; however, there is no literature on specific factors that predict its use in diffuse large b-cell lymphoma (DLBCL) patients. Therefore, the prevalence of palliative care utilization and predictors of palliative care utilization among patients with DLBCL were examined. Methods: Data from the National Inpatient Sample (NIS) collected between 2016 to 2018 were used for all analyses. Multivariable logistic regression models were used to examine the predictors of palliative care utilization among hospitalized patients with DLBCL. Descriptive analyses were used to explore the overall prevalence of palliative care receipt in this population. Results: Of the 41,789 hospitalizations, 7.1% of patients used palliative care during hospitalization, while 4.8% utilized palliative care and were discharged alive. DLBCL patients aged 70 and older had 1.3 times (95% CI: 1.14-1.41) higher odds of utilizing palliative care compared to those less than 70 years. Relative to Medicare/Medicaid patients, those with other types of insurance were 1.7 times (95% CI: 1.34-2.05) more likely to receive palliative care. Those who were either transferred to a facility/discharged with home health (AOR: 6.23; 95% CI: 5.21-7.44) or died during hospitalization (AOR: 45.17; 95% CI: 36.98-55.17) had higher odds of receiving palliative care when relative to those with a routine hospital discharge. Other associated factors were type of admission, length of stay, chemotherapy receipt, and number of comorbidities. Conclusions: The prevalence of palliative care utilization was low and factors predicting utilization in our population were identified. Our findings highlight the need to increase awareness among medical oncologists on the need to involve the palliative care team early in the management of hospitalized patients with DLBCL.

show abstract

Section: Introductionmentioning

confidence: 99%